Curious about the PAVING study? Recorded webinar available!


Decisions about whether to approve new and emerging gene therapies are impeded by the associated uncertainties, e.g. long-term outcomes. In this complex context, the PAVING study investigated haemophilia patients’ preferences for gene therapies. Learn about how the preference study was designed, what the results were, and what the impact might be.

The recoded webinar is now available on the PREFER YouTube channel. You can watch it in its entirety or scroll to find the parts below. If you want to be invited to future PREFER webinars, sign up for our newsletter! Or have a look at our event calendar to find out what has been planned already.

Introduction to the decision making and clinical studies & objectives 

Prof. Isabelle Huys IMI PREFER deputy coordinator, KU Leuven

Desig of the PAVING study 

Brett Hauber, Senior Director, Patient Preference Elicitation, Pfizer, United States

Results and conclusions

Eline van Overbeeke, Health Economics and Outcomes Research Manager, Pfizer

Last modified: 2021-11-10